West Family Investments Inc. Purchases 1,762 Shares of Medtronic PLC $MDT

West Family Investments Inc. boosted its position in Medtronic PLC (NYSE:MDT) by 43.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 5,772 shares of the medical technology company’s stock after purchasing an additional 1,762 shares during the period. West Family Investments Inc.’s holdings in Medtronic were worth $503,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Schroder Investment Management Group grew its holdings in Medtronic by 21.5% in the 2nd quarter. Schroder Investment Management Group now owns 4,222,638 shares of the medical technology company’s stock valued at $368,087,000 after buying an additional 747,244 shares in the last quarter. Norges Bank acquired a new position in shares of Medtronic in the second quarter valued at about $1,432,698,000. Level Four Advisory Services LLC grew its position in shares of Medtronic by 2.6% during the 2nd quarter. Level Four Advisory Services LLC now owns 42,526 shares of the medical technology company’s stock worth $3,707,000 after purchasing an additional 1,074 shares in the last quarter. Bank of Nova Scotia Trust Co. raised its position in shares of Medtronic by 0.9% in the second quarter. Bank of Nova Scotia Trust Co. now owns 111,420 shares of the medical technology company’s stock valued at $9,712,000 after buying an additional 956 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. increased its stake in Medtronic by 2.9% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 7,154 shares of the medical technology company’s stock worth $632,000 after acquiring an additional 200 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Down 0.5%

Shares of MDT stock opened at $104.53 on Friday. The firm has a market cap of $134.00 billion, a P/E ratio of 28.79, a PEG ratio of 2.42 and a beta of 0.77. The company has a 50 day moving average of $96.06 and a 200-day moving average of $91.66. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MDT shares. UBS Group boosted their price target on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Daiwa Capital Markets boosted their target price on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Morgan Stanley boosted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.44.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.